#United States #New York #Securities Fraud #Rosen Law Firm #Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Securities Fraud Lawsuit: An Overview

Background

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is currently facing a class action lawsuit over allegations of securities fraud. The esteemed Rosen Law Firm has issued a reminder for investors who acquired securities during the specified Class Period—from November 2, 2023, to October 30, 2024—to consider joining the lawsuit before the lead plaintiff deadline of March 10, 2025.

Understanding the Class Action

If you purchased Regeneron securities within the defined timeline, you might be eligible for compensation through a contingency fee arrangement, meaning you won’t incur upfront legal expenses. By joining the class action, you could potentially benefit from a collective legal approach that aims to hold the company accountable for its alleged misrepresentations.

To participate, interested investors are encouraged to visit the Rosen Law Firm's website here or contact their office directly for more information.

Why This Lawsuit Matters

The crux of the lawsuit revolves around claims that Regeneron provided misleading statements regarding its financial health, particularly concerning its well-known product, Eylea. According to the allegations, Regeneron intentionally misrepresented how its pricing and business operations were affecting its reported sales figures. Specific claims include:

1. Payment of Credit Card Fees: Regeneron allegedly paid fees to distributors tied to the stipulation that they wouldn’t pass those charges onto customers using credit cards. This practice reportedly resulted in artificially inflated sales figures for Eylea.

2. Price Concessions Misrepresentation: It is claimed that these financial arrangements allowed Regeneron to lower the prices of Eylea without disclosing these concessions in its financial reports, breaching the False Claims Act.

3. Investment Misleading: The lawsuit asserts that Regeneron's statements about its business prospects and financial outlook were materially misleading, which led to substantial investor losses when the truth of the financial practices came to light.

Importance of Qualified Representation

Rosen Law Firm emphasizes the necessity for investors to choose a legal team with a proven track record in securities class actions. Many firms simply act as middlemen rather than actively litigating cases. Rosen Law Firm prides itself on its history of achieving significant settlements on behalf of its clients, including a notable record against international companies.

It's crucial for potential class members to do due diligence when selecting an attorney to ensure their interests are effectively represented in court.

Next Steps for Investors

If you believe that you may have been impacted by Regeneron’s conduct during the Class Period, it is essential to act promptly. Here are the steps you should consider:

• - Contact Legal Counsel: Reach out to the Rosen Law Firm or another qualified attorney with experience in securities litigation.
• - Documentation: Gather any purchase records and relevant documents associated with your Regeneron investments.
• - Deadline Awareness: Be mindful of the March 10, 2025 deadline to file as a lead plaintiff if you wish to take a more active role in the proceedings.

Investors are reminded that until a class is certified, they are not officially represented unless they retain legal counsel. The chances to realize a recovery are not contingent on serving as lead plaintiff, allowing for flexibility in participation.

Stay Informed

For ongoing updates regarding this case and others, it is advisable to follow the Rosen Law Firm on social media platforms like LinkedIn, Twitter, and Facebook.

In summation, Regeneron investors possess a unique opportunity to seek justice and possible compensation due to the alleged securities violations affecting their investments. In ensuring that such actions are addressed, the integrity of the market and investor confidence can be upheld.